These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


Pubmed for Handhelds

PUBMED FOR HANDHELDS

Journal Abstract Search

148 related items for PubMed ID: 17027946

  • 1.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 2. Comparing pharmacokinetic and pharmacodynamic profiles in female rats orally exposed to lovastatin by gavage versus diet.
    Martín-Jiménez T, Lindeblad M, Kapetanovic IM, Chen Y, Lyubimov A.
    Chem Biol Interact; 2008 Jan 30; 171(2):142-51. PubMed ID: 17854789
    [Abstract] [Full Text] [Related]

  • 3. Comparison of pharmacokinetic and pharmacodynamic profiles of aspirin following oral gavage and diet dosing in rats.
    Kapetanovic IM, Bauer KS, Tessier DM, Lindeblad MO, Zakharov AD, Lubet R, Lyubimov A.
    Chem Biol Interact; 2009 May 15; 179(2-3):233-9. PubMed ID: 18992230
    [Abstract] [Full Text] [Related]

  • 4.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 5. Pharmacokinetic profiles in rats after intravenous, oral, or dermal administration of dapsone.
    Helton DR, Osborne DW, Pierson SK, Buonarati MH, Bethem RA.
    Drug Metab Dispos; 2000 Aug 15; 28(8):925-9. PubMed ID: 10901702
    [Abstract] [Full Text] [Related]

  • 6. Absorption of sulindac from a novel (Pro-SorbTM) liquid formulation.
    Kanfer I, Brown C, Konings M, Swarbrick J.
    Biopharm Drug Dispos; 1996 Apr 15; 17(3):209-21. PubMed ID: 8983396
    [Abstract] [Full Text] [Related]

  • 7. Phase I trial of exisulind (sulindac sulfone, FGN-1) as a chemopreventive agent in patients with familial adenomatous polyposis.
    van Stolk R, Stoner G, Hayton WL, Chan K, DeYoung B, Kresty L, Kemmenoe BH, Elson P, Rybicki L, Church J, Provencher K, McLain D, Hawk E, Fryer B, Kelloff G, Ganapathi R, Budd GT.
    Clin Cancer Res; 2000 Jan 15; 6(1):78-89. PubMed ID: 10656435
    [Abstract] [Full Text] [Related]

  • 8.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 9.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 10.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 11.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 12. Comparative chlorpyrifos pharmacokinetics via multiple routes of exposure and vehicles of administration in the adult rat.
    Smith JN, Campbell JA, Busby-Hjerpe AL, Lee S, Poet TS, Barr DB, Timchalk C.
    Toxicology; 2009 Jun 30; 261(1-2):47-58. PubMed ID: 19397948
    [Abstract] [Full Text] [Related]

  • 13.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 14. Sulindac inhibits colorectal tumour growth, but not prostaglandin synthesis in the rat.
    Charalambous D, Skinner SA, O'Brien PE.
    J Gastroenterol Hepatol; 1998 Dec 30; 13(12):1195-200. PubMed ID: 9918425
    [Abstract] [Full Text] [Related]

  • 15. Topical sulindac combined with hydrogen peroxide in the treatment of actinic keratoses.
    Resnick L, Rabinovitz H, Binninger D, Marchetti M, Weissbach H.
    J Drugs Dermatol; 2009 Jan 30; 8(1):29-32. PubMed ID: 19180893
    [Abstract] [Full Text] [Related]

  • 16. Short-term modulation of cell proliferation and apoptosis and preventive/therapeutic efficacy of various agents in a mammary cancer model.
    Christov K, Grubbs CJ, Shilkaitis A, Juliana MM, Lubet RA.
    Clin Cancer Res; 2007 Sep 15; 13(18 Pt 1):5488-96. PubMed ID: 17875779
    [Abstract] [Full Text] [Related]

  • 17. Possibility of enterohepatic recycling of ketoprofen in dogs.
    Granero GE, Amidon GL.
    Int J Pharm; 2008 Feb 12; 349(1-2):166-71. PubMed ID: 17890028
    [Abstract] [Full Text] [Related]

  • 18. Pharmacokinetic and pharmacodynamic interactions of tolfenamic acid and marbofloxacin in goats.
    Sidhu PK, Landoni MF, Lees P.
    Res Vet Sci; 2006 Feb 12; 80(1):79-90. PubMed ID: 16005916
    [Abstract] [Full Text] [Related]

  • 19. Population pharmacokinetic model for cancer chemoprevention with sulindac in healthy subjects.
    Berg AK, Mandrekar SJ, Ziegler KL, Carlson EC, Szabo E, Ames MM, Boring D, Limburg PJ, Reid JM, Cancer Prevention Network.
    J Clin Pharmacol; 2013 Apr 12; 53(4):403-12. PubMed ID: 23436338
    [Abstract] [Full Text] [Related]

  • 20. Pharmacokinetics of oral fenretinide in neuroblastoma patients: indications for optimal dose and dosing schedule also with respect to the active metabolite 4-oxo-fenretinide.
    Formelli F, Cavadini E, Luksch R, Garaventa A, Villani MG, Appierto V, Persiani S.
    Cancer Chemother Pharmacol; 2008 Sep 12; 62(4):655-65. PubMed ID: 18066548
    [Abstract] [Full Text] [Related]

    Page: [Next] [New Search]
    of 8.